INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 420m ago
HOUSE PTR19m ago
SEC 13F19m ago
ROBINHOOD CHAIN19m ago
SEC FORM 4/Option exerciseVerified data

Bharucha David reported MIST

Chief Medical Officer · Milestone Pharmaceuticals Inc. · Common Shares

Side
M
Value
—
Shares
20.1K
Price
—
Executed
Jan 26, 2026
Disclosed
Jan 28, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 26 executedJan 28, 2026 disclosed

MIST · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+5 / 25

No reported dollar value · 19.1% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · MIST

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    DS
    Duty StuartDirector
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    77.0K sh
    		Jun 10, 2026Jun 12, 2026
    traded Jun 10, 2026
    		+2dSEC FORM 4

    Evidence

    5
    NE
    Nelson Jeffrey EdwardChief Operating Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    136.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    5
    BD
    Bharucha DavidChief Medical Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    204.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    5
    BD
    Bharucha DavidChief Medical Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    136.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    5
    NE
    Nelson Jeffrey EdwardChief Operating Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    204.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    36
    HA
    Hasija AmitCFO & EVP of Corp. Development
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    100.0K sh
    		Dec 12, 2025Jan 28, 2026
    traded Dec 12, 2025
    		+47dSEC FORM 4

    Evidence

    24
    NE
    Nelson Jeffrey EdwardChief Operating Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    100.0K sh
    		Dec 12, 2025Jan 28, 2026
    traded Dec 12, 2025
    		+47dSEC FORM 4

    Evidence

    66
    NE
    Nelson Jeffrey EdwardChief Operating Officer
    MISTMilestone Pharmaceuticals Inc.
    Open-market sale
    		SELL$135K
    58.0K sh
    		Dec 15, 2025Jan 28, 2026
    traded Dec 15, 2025
    		+44dSEC FORM 4

    Evidence

    13
    NE
    Nelson Jeffrey EdwardChief Operating Officer
    MISTMilestone Pharmaceuticals Inc.
    Option exercise
    		M—
    20.1K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    36
    NE
    Nelson Jeffrey EdwardChief Operating Officer
    MISTMilestone Pharmaceuticals Inc.
    Open-market sale
    		SELL$24K
    12.2K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    24
    NE
    Nelson Jeffrey EdwardChief Operating Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    100.0K sh
    		Dec 12, 2025Jan 28, 2026
    traded Dec 12, 2025
    		+47dSEC FORM 4

    Evidence

    17
    NE
    Nelson Jeffrey EdwardChief Operating Officer
    MISTMilestone Pharmaceuticals Inc.
    Option exercise
    		M—
    20.1K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    36
    BD
    Bharucha DavidChief Medical Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    100.0K sh
    		Dec 12, 2025Jan 28, 2026
    traded Dec 12, 2025
    		+47dSEC FORM 4

    Evidence

    24
    BD
    Bharucha DavidChief Medical Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    100.0K sh
    		Dec 12, 2025Jan 28, 2026
    traded Dec 12, 2025
    		+47dSEC FORM 4

    Evidence

    17
    BD
    Bharucha DavidChief Medical Officer
    MISTMilestone Pharmaceuticals Inc.
    Option exercise
    		M—
    20.1K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    62
    HA
    Hasija AmitCFO & EVP of Corp. Development
    MISTMilestone Pharmaceuticals Inc.
    Open-market sale
    		SELL$135K
    58.0K sh
    		Dec 15, 2025Jan 28, 2026
    traded Dec 15, 2025
    		+44dSEC FORM 4

    Evidence

    13
    HA
    Hasija AmitCFO & EVP of Corp. Development
    MISTMilestone Pharmaceuticals Inc.
    Option exercise
    		M—
    20.1K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    36
    HA
    Hasija AmitCFO & EVP of Corp. Development
    MISTMilestone Pharmaceuticals Inc.
    Open-market sale
    		SELL$24K
    12.2K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    24
    HA
    Hasija AmitCFO & EVP of Corp. Development
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    100.0K sh
    		Dec 12, 2025Jan 28, 2026
    traded Dec 12, 2025
    		+47dSEC FORM 4

    Evidence

    36
    ML
    Muller LorenzChief Commercial Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    100.0K sh
    		Dec 12, 2025Jan 28, 2026
    traded Dec 12, 2025
    		+47dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001910985-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 26, 2026
    Published
    Jan 28, 2026
    Ingested by INSIDER
    Nov 5, 04:20 UTC
    Last re-read
    Nov 5, 04:20 UTC

    Extracted facts

    Filer
    Bharucha David
    Role
    Chief Medical Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Milestone Pharmaceuticals Inc.
    Ticker
    MIST
    Shares
    20.1K
    Execution date (reported)
    Jan 26, 2026
    Owned after transaction
    125.4K shares
    Days from execution to publication
    2

    What this establishes

    Bharucha David filed this Form 4 reporting a option exercise of MIST on Jan 26, 2026. It became public on Jan 28, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Medical Officer
    Bharucha Davidcik:0001910985
    Issuer
    Milestone Pharmaceuticals Inc.cik:0001408443

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.